Valproate and other anticonvulsants for psychiatric disorders.
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000085:Acetates / Q000627:therapeutic use; D000328:Adult; D000588:Amines; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy*; D002220:Carbamazepine / Q000627:therapeutic use; D003072:Cognition Disorders / Q000139:chemically induced; D003509:Cyclohexanecarboxylic Acids; D004244:Dizziness / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077206:Gabapentin; D006330:Heart Defects, Congenital / Q000139:chemically induced; D006801:Humans; D000077213:Lamotrigine; D009325:Nausea / Q000139:chemically induced; D009765:Obesity / Q000139:chemically induced; D013262:Stevens-Johnson Syndrome / Q000209:etiology*; D000077236:Topiramate; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use; D014635:Valproic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D014151:Anti-Anxiety Agents; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D014227:Triazines; D000077236:Topiramate; D005632:Fructose; D002220:Carbamazepine; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D000077206:Gabapentin; D000077213:Lamotrigine